The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Japan’s Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions […]
ABBOTT PARK, Ill., April 18, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2018. First-quarter worldwide sales of $7.4 billion increased 16.7 percent on a reported basis and 6.9 percent on an organic* basis. Reported diluted EPS from continuing operations […]
ABBOTT PARK, Ill., April 11, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by high-resolution light-based imaging technology—called optical coherence tomography (OCT)—compared to a common X-ray-guided technique called angiography. […]
ABBOTT PARK, Ill., March 29, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New […]
ABBOTT PARK, Ill., March 21, 2018 /PRNewswire/ — Abbott (NYSE: ABT) will announce its first-quarter 2018 financial results on Wednesday, April 18, 2018, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 […]
ABBOTT PARK, Ill., March 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company’s MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart […]
ORLANDO, Fla., March 11, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device (LVAD) trial in the world to evaluate patients in need of both short-term and long-term […]
ABBOTT PARK, Ill., March 6, 2018 /PRNewswire/ — Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world’s smallest mechanical heart valve, that will allow doctors to treat babies and toddlers […]
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ — Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics’ SurVeil® drug-coated balloon to treat the superficial femoral […]
ABBOTT PARK, Ill., Jan. 11, 2018 – Abbott today announced CE Mark approval for the company’s new Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, a product designed to advance cardiac mapping during cardiac ablation to treat patients with complex cardiac […]
